Immune modulator for immunotherapy and vaccine formulation
AssigneesVirginia Commonwealth University, Health Research, Inc.
InventorsXiang-Yang Wang, Xiaofei Yu, John R. Subjeck
Life of this patent
Estimating the term…
Abstract
A recombinant Flagrp170 protein and pharmaceutical compositions comprising a Flagrp170 protein and related molecules encoding same, and cells presenting such a protein are provided. The Flagrp170 protein comprises an NF-κB-activating domain of Flagellin and an ATP-binding domain truncated Grp170. The pharmaceutical compositions of the invention can be used for the treatment or prevention of cancer or infectious disease.
Claims19
A fusion construct comprising a polynucleotide encoding an NF-κB-activating domain of Flagellin in operable linkage with a polynucleotide encoding an ATP-binding domain truncated Grp170, wherein the NF-κB-activating domain of Flagellin comprises N-terminal amino acids 2-175 and C-terminal amino acids 402-495 of SEQ ID NO:
- 8, and wherein the ATP-binding domain truncated Grp170 consists of amino acids 431-994 of SEQ ID NO:
- 2 or 3.
Dependencies are inferred from the claim text.